Introduction
Pulmonary embolism is a life threatening condition (1) (2) (3) (4) (5) (6) . Pregnancy is among the risk factors for pulmonary embolism (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . There is reluctance about using thrombolytics during pregnany due to potential teratogenic effects. Valproic acid is one of the most commonly used antiepileptic agent however, its use during pregnancy is controversial because of its teratogenic potential (15, 16) . Among adverse effects of valproic acid, elevated liver enzymes and thrombocytopenia have been reported (17) . Moreover, product literature warns that pregnant women using valproic acid should be monitored for low fibrinogen and platelets and the potential for bleeding. The present case report describes successful treatment of massive pulmonary embolism with tissue plasminogen activator (t-PA), caused by mobile right atrial thrombus in a first trimester pregnant women using valproic acid, which has not been reported previously.
Case Report
Eight months previously, a 30-year-old pregnant women presented to the emergency department with acute onset of dyspnea, presyncope, fatigue and palpitation. Her past medical history revealed that she had epilepsy and had been using valproic acid 500 mg/day for 15 years. She was in her 8th week of pregnancy. Her vital signs were as follows: blood pressure, 85/55 mm Hg; pulse rate, 116/ min; respiratory rate, 23/min; temperature, 37.7°C and pulse oximetry, 88%. On electrocardiography, she had sinus tachycardia, incomplete right bundle branch block, and S wave in lead I and a Q wave and T wave in lead III. Physical examination revealed a. tricuspid regurgitation murmur, an accentuated P2, pale, cold and sweaty skin, and faint and filiform peripheral pulses. Transthoracic echocardiography revealed normal left ventricular and atrial chamber sizes and function However, there was a significant increase in right ventricular size with free wall hypokinesis sparing the apical region (McConnell sign). There was a semi-mobile worm-like thrombus in the right atrium, which was entering into the right ventricle at each diastole ( Figure 1 , left panel). There was moderate tricuspid regurgitation with pulmonary hypertension (estimated pulmonary artery pressure was approximately 50 mmHg) and the main pulmonary artery was dilated. Emergency obstetric examination of the patient was compatible with a 8 week pregnancy with normal fetal growth. She was then quickly transferred to the coronary care unit with the diagnosis of massive pulmonary embolism. Because she and her husband refused any surgical treatment option due to her pregnancy, we gave her 100 mg continuous t-PA infusion over 2 hours. We started unfractionated heparin after t-PA according to activated partial thromboplastin time measurements.
After t-PA, her signs and symptoms resolved completely. Transthoracic echocardiographic control revealed that the right atrial thrombus had disappeared and right ventricular size and function normalized (Figure 1, right panel) . Estimated pulmonary artery pressure was 22 mmHg and there was only minimal tricuspid regurgitation. Her laboratory examinations and lower extremity ultrasound were within normal limits and were not in accordance with any possible association with vascular pathologies or hematological disorders.
She was discharged with enoxaparin 1mg/kg twice daily which was switched to unfractionated heparin in the 34 th week of pregnancy and valproic acid 500 mg/day. During follow-ups, she was free of any signs or symptoms and gave birth to a healthy baby by spontaneous vaginal delivery. On her last visit, she was completely healthy and the baby was free of any problem and deformity.
Discussion
Pulmonary embolism is a life threatening condition (1) (2) (3) (4) (5) (6) . Pregnany is among the risk factors and the risk of deep venous thrombosis and pulmonary emboli is increased four to six times due to the procoagulant state of pregnancy (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Treatment strategies of massive pulmonary embolism include thrombolysis and surgical/interventional embolectomy. T-PA is the recommended thrombolytic agent. There is reluctance about using thrombolytics during pregnany due to the potential teratogenic effects. Although not subject to randomized studies, there are successful reports of thrombolytic treatment with t-PA during pregnancy (4-14). Leonhardt et al. states that t-PA does not cross the placenta and complication rates of thrombolytic therapy in pregnants are not higher than in the large randomized trials in the non-pregnant population (3). Moreover, it is suggested that the risk of surgical embolectomy with cardiopulmonary bypass might outweigh the risk of thrombolytics for the mother and fetus.
Valproic acid is one of the most commonly used antiepileptic agent. During pregnancy, use of valproic acid is controversial because it is difficult to balance the loss of seizure control and an elevated risk of major congenital malformations (15, 16) . When used during pregnancy, use of the lowest possible effective dose of (<1000 mg/day) is recommended with close antenatal monitoring (15, 16) . Among adverse effects of valproic acid use, elevated liver enzymes and thrombocytopenia have been reported (17) . Moreover, product literature warns that pregnant women using valproic acid should be In conclusion, the present case report describes successful treatment of massive pulmonary embolism with t-PA, caused by mobile right atrial thrombus in a first trimester pregnant women using valproic acid, which has not been reported previously.
